Dossier
sigvotatug vedotin
Coverage of sigvotatug vedotin in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about FDA reforming clinical trials, a Pfizer setback, and much more news
Pfizer disclosed that its experimental lung cancer drug, sigvotatug vedotin, failed to show a statistically significant improvement over docetaxel in a clinical trial. The U.S. Food and Drug Administration announced a pilot program to accelerate early-stage clinical trials, aiming to reduce development timelines and counter Chinese dominance in the field.
- STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial
Pfizer's experimental lung cancer drug sigvotatug vedotin failed in a clinical trial, which was expected to replace the chemotherapy docetaxel. The drug was acquired through Pfizer's $43 billion purchase of Seagen in 2023.